CLL/LPD

Laboratory assay overview

Chronic Lymphocytic leukemia is the most common leukemia in the Western world. The disease is chronic and most patients may not require therapy in the early stage of the disease. However, in some patients the disease can be aggressive and within a year the tumor mass may increase significantly imposing serious health problems to the patient. It is difficult to determine based on clinical presentation which patient will progress faster than the others. Therefore, there is a need to use more accurate prognostic indicator to predict the clinical course of this disease. The recent advances in CLL therapy and biology made it possible to develop new tests and a combination of these tests.